The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00
Please note that this agenda is final and is subject to change prior to the meeting.
5. Appraisal of topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (including reviews of technology appraisal guidance 91 and 222) [ID468]
5.1 Declarations of interest - Part 1 only (open session)
5.2. Introduction by the Chair, Dr Jane Adam- Part 1 only (open session)
5.3. Presentation by the Chair, Dr Jane Adam- Part 1 and Part 2 (open and closed session)
5.4. Agreement on the content of the Appraisal Consultation Document (ACD) - Part 2 only (closed session)
6. Appraisal of olaparib for maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy [ID735]
6.1 Declarations of interest - Part 1 only (open session)
6.2. Introduction by the Chair, Dr Jane Adam- Part 1 only (open session)
6.3. Presentation by the Chair, Dr Jane Adam- Part 1 and Part 2 (open and closed session)
6.4. Agreement on the content of the Final Appraisal Determination (FAD) - Part 2 only (closed session)
Date, time and venue of next meeting
Next Technology Appraisal (Committee A) Meeting: Wednesday, 25th November 2015, at 10:00am, at Prospero House, 241 Borough High Street, London SE1 1GA
To print this agenda, please right click and select ‘Print’ from the menu
You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
The closing date for registration is Tuesday 13th October 2015. Please note that it may not be possible to accept late registration requests.
Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Manisha Young
Please note that registrants wishing to conduct a research study on the committee meeting and/or NICE processes will require prior permission and should contact NICE Enquiry Handling by email email@example.com Further information about conducting research is also available in our Common Questions and Answers about meetings in public document.